Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the...
Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the likelihood that "compelling early data associated with the company's nucleic acid assays … will increase interest among leading cancer centers in further exploring the clinical utility" of complementing or replacing tumor tissue biopsies.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs